Studies reveal potential of HPV vaccine to substantially reduce incidence of cervical cancer and suggest screening programs could be modified

November 08, 2011

The bivalent human papillomavirus (HPV) vaccine (Cervarix, GlaxoSmithKline) offers excellent protection against the more serious immediate precursor to invasive cervical cancer (ICC), particularly when given to young adolescent girls before they become sexually active. The findings of two studies published Online First in The Lancet Oncology, also show that the vaccine partially protects against four other cancer-causing HPV types not targeted by the formulation, that together with HPV16/18, cause about 85% of cervical cancer worldwide.

"Provided that organised vaccination programmes achieve high coverage in early adolescents before sexual debut, HPV vaccination has the potential to substantially reduce the incidence of cervical cancer, probably allowing modification of screening programmes... when conducted alongside vaccination strategies", explains one of the lead authors, Matti Lehtinen from the University of Tampere in Finland.

The bivalent vaccine targets HPV types 16 and 18 that are responsible for about 70% of cervical cancers. Most studies of vaccine efficacy have focused on prevention of cervical intraepithelial neoplasia 2 (CIN2) or higher. However, CIN3 is generally believed to be a more reproducible and predictive endpoint than CIN2, and often progresses to ICC.

In 2009, the PApilloma TRIal against Cancer In young Adults (PATRICIA), the largest study of HPV16/18 vaccine efficacy to date, reported that the bivalent vaccine had high efficacy against the precancerous cervical lesions CIN2+.

The study included almost 20 000 healthy women aged 15󈞅 years from 14 countries in Asia-Pacific, Europe, Latin America, and North America. Women were randomly assigned to receive the bivalent HPV vaccine or a control (hepatitis A) vaccine, given in three doses at enrolment, 1 month, and 6 months.

Here, the researchers report the final analysis (after 4 years of follow-up) that examined the efficacy of the vaccine against high-grade cervical precancers (CIN3+), the early development of adenocarcinoma (AIS), and 12 other cancer-causing HPV types not targeted by the vaccine.

In young women not already infected with HPV, the vaccine proved over 93% effective against CIN3+ and prevented 100% of AIS regardless of HPV type compared with nearly 46% efficacy against CIN3+ and 77% against AIS in the general population of women. Amongst the previously unexposed young women, the vaccine prevented 100% of HPV16/18-related CIN3+, compared with nearly 46% in the general population regardless of prior exposure to HPV.

The authors conclude: "Appropriate effectiveness and implementation studies assessing the combination of vaccination and new screening strategies are warranted."

In a second study, the vaccine showed increased cross-protection against other cancer-causing HPV types 31, 33, 45, and 51 in different cohorts representing diverse groups of women.

"There is a particularly high risk of HPV-33 infections progressing to cervical lesions, and HPV-45 is over-represented in adenocarcinoma...Our results show that cross-protective efficacy might provide substantial additional protection against cervical cancer beyond protection conferred against HPV-16/18", concludes Cosette Wheeler from the University of New Mexico Health Sciences Center, Department of Pathology, in the USA, one of the lead authors of the study.

In a Comment, Mark Schiffman and Sholom Wacholder from the National Cancer Institute, Rockville, MD, USA remark: "We believe that increasing coverage, particularly of sexually-naïve adolescent females, is now the most important public-health issue in HPV vaccination efforts."

They add: "We are particularly concerned about low vaccination rates in areas where cervical cancer incidence and mortality are high because of inadequate alternative prevention through effective cervical screening, and where nine of 10 cervical cancers deaths occur...The current vaccines are too expensive and difficult to deliver for many low-resource regions."
Professor Matti Lehtinen, University of Tampere, Tampere, Finland. T) +358 50 3969648 E)

Professor Cosette Wheeler, University of New Mexico Health Sciences Center, Albuquerque, USA. T) +1505 269 5817 E)

Dr Mark Schiffman, National Cancer Institute, Rockville, MD, USA. Via NCI Press Office T) +1 301 496 6641 E)


Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to